MedTrace Logo

Pulse Steroid Injection in Refractory Rheumatoid Arthritis

NCT06456489 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 268

Last updated 2024-06-13

No results posted yet for this study

Summary

Remission or low disease activity in active rheumatoid arthritis

Conditions

  • Active Rheumatoid Arthritis

Interventions

DRUG

Solumedrol

125 mg methylprednisolone intravenous pulse on 2 consecutive days

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2024-09-30
Completion
2024-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06456489 on ClinicalTrials.gov